Home  /  Resource Library  /  Long-Term (>4 Year and >5 Year) Overall Survival (OS) By 12 and 24 Month Event Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Long-Term (>4 Year and >5 Year) Overall Survival (OS) By 12 and 24 Month Event Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

ASH 2021